What is Zacks Research's Forecast for CPRX FY2025 Earnings?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research boosted their FY2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research note issued on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $2.08 per share for the year, up from their prior forecast of $2.02. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $2.52 EPS.

A number of other equities analysts have also issued reports on CPRX. Robert W. Baird raised their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Stephens restated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ CPRX traded up $0.07 during midday trading on Monday, reaching $25.36. The company had a trading volume of 929,880 shares, compared to its average volume of 1,112,398. The business's 50-day simple moving average is $23.60 and its 200 day simple moving average is $22.71. The stock has a market cap of $3.09 billion, a P/E ratio of 21.49, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals has a 1 year low of $14.75 and a 1 year high of $26.16.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,630,912.64. The trade was a 74.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock worth $8,710,000 after acquiring an additional 50,888 shares in the last quarter. Spire Wealth Management increased its holdings in Catalyst Pharmaceuticals by 1,342.9% in the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after acquiring an additional 13,429 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Catalyst Pharmaceuticals by 91.5% in the 4th quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock worth $1,241,000 after acquiring an additional 28,407 shares in the last quarter. Finally, abrdn plc purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $10,115,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.